The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Let's see what GB has planned for the share price, was 70s until the presentation. Just got a decent entry price, let's see if GB has it in him to get this over the 40s pre Christmas.
Feel for you classhero, hopefully you can jump back in today. There will also be others for you if you can find this.
Crypto, see below link. DYOR
https://www.investopedia.com/terms/c/cupandhandle.asp
Main ramper Top Aim Stocks has apparently been buying at 11p so for anybody who got stund hopefully 4p and sell at 10p
Pump and dump? Hope those ramping and getting others sucked in get caught out and lose all one day. Luckily never bought in today.
To the regulars who have been posting information about trials, interferon and various other updates.
I cannot find your posts now (too many to go through) and it would have been nice to read all the messages of those who held during the low 30s as today was our day!
Good luck to you and all those joining now, hope we can get some good offers for the company.
Have there been reports they want to takeover?
Why would they sell Stemprinter so low when it is best in class?
Afternoon all
Not sure if posted.
https://youtu.be/ggFJ-XX6C5M
Anything to do with us?
(Bloomberg) -- Lansdowne Partners is shutting its main hedge fund in a shift away from short-selling after being hit by some of its worst-ever losses.
The London-based investment firm is closing the $2.8 billion Lansdowne Developed Markets Fund, according to a person with knowledge of the matter. Investors could withdraw their money or move it into the Lansdowne Developed Markets Long Only Fund or a new LDM Opportunities Fund, which will invest in early-stage companies, said the person, who asked not to be identified because the information is private.
The firm will continue to bet against companies in some of its other funds.
A spokesman for Lansdowne Partners declined to comment.
The move marks a dramatic retreat by one of the world’s most famous equity long/short hedge funds, and comes after poor performance in both rising and falling markets. The firm’s main hedge fund is run by Peter Davies and Jonathon Regis, and tumbled 13% in March’s rout, the biggest monthly decline since it started trading almost two decades ago. It was down 23.3% in the first half of the year, according to a letter to investors seen by Bloomberg.
Years of poor returns have led to outflows from the firm, with its assets dropping to $9.8 billion in June from a peak of nearly $22 billion.
The firm has told investors that it’s become harder to make money with short bets against companies, and it’s finding more opportunities in long bets and investment in early-stage companies, the person said.
Lansdowne was already managing more money in its long-only funds than in other strategies. At the start of March, only about 45% of the firm’s assets were in long-short money pools.
The news of Lansdowne’s fund closure was reported earlier by Institutional Investor.
(Adds background, fund details starting in fifth paragraph)
©2020 Bloomberg L.P.
Nolupus, trust you've done you research before going in and did factor for both scenarios. I have enjoyed your posts looking from a different perspective. Do you think we will have success in any of the 3 trials?
If it goes to 10/15p from here then for me it is what it is now.